Anthera Pharmaceuticals

Anthera Pharmaceuticals is a drug development company focused on developing and advancing promising clinical products for the treatment of severe inflammatory diseases. The company has acquired rights to a series of clinical and preclinical products worldwide (excluding Japan) that inhibit the enzymatic activity of secretory phospholipase A2 – a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes, prostacyclins, and other inflammatory mediators. These potent compounds inhibit novel upstream steps in the inflammatory cascade and have the potential to address a variety of diseases.